NASDAQ:ALGS - Aligos Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.50
  • Forecasted Upside: 21.14 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$28.48
▼ -2.73 (-8.75%)
1 month | 3 months | 12 months
Get New Aligos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALGS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALGS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$34.50
▲ +21.14% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Aligos Therapeutics in the last 3 months. The average price target is $34.50, with a high forecast of $42.00 and a low forecast of $28.00. The average price target represents a 21.14% upside from the last price of $28.48.

Buy

The current consensus among 4 polled investment analysts is to buy stock in Aligos Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2021Piper SandlerInitiated CoverageOverweight$47.00 ➝ $35.00High
i
4/1/2021Jefferies Financial GroupReiterated RatingBuy$42.00High
i
3/24/2021Piper SandlerBoost Price TargetOverweight$35.00 ➝ $40.00High
i
11/10/2020Jefferies Financial GroupInitiated CoverageBuy$26.00High
i
11/10/2020JPMorgan Chase & Co.Initiated CoverageOverweight$33.00High
i
11/10/2020Piper SandlerInitiated CoverageOverweight$35.00High
i
11/10/2020Cantor FitzgeraldInitiated CoverageOverweight$28.00High
i
Rating by A. Young at Cantor Fitzgerald
(Data available from 6/16/2016 forward)
Aligos Therapeutics logo
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-Ã agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $28.48
$27.69
$31.21

50 Day Range

MA: $25.86
$20.30
$33.60

52 Week Range

Now: $28.48
$12.82
$37.51

Volume

146,058 shs

Average Volume

75,836 shs

Market Capitalization

$1.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aligos Therapeutics?

The following Wall Street analysts have issued reports on Aligos Therapeutics in the last twelve months: Cantor Fitzgerald, Jefferies Financial Group Inc., JPMorgan Chase & Co., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for ALGS.

What is the current price target for Aligos Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Aligos Therapeutics in the last year. Their average twelve-month price target is $34.50, suggesting a possible upside of 21.1%. Jefferies Financial Group Inc. has the highest price target set, predicting ALGS will reach $42.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $28.00 for Aligos Therapeutics in the next year.
View the latest price targets for ALGS.

What is the current consensus analyst rating for Aligos Therapeutics?

Aligos Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALGS will outperform the market and that investors should add to their positions of Aligos Therapeutics.
View the latest ratings for ALGS.

What other companies compete with Aligos Therapeutics?

How do I contact Aligos Therapeutics' investor relations team?

The company's listed phone number is 800-466-6059 and its investor relations email address is [email protected] The official website for Aligos Therapeutics is www.aligos.com.